Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Review

Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues

Authors: Hongqing Zhuang, Siyu Shi, Zhiyong Yuan, Joe Y. Chang

Published in: Molecular Cancer | Issue 1/2019

Login to get access

Abstract

Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism forradiation brain necrosis development. Bevacizumab alleviates brain edema symptoms caused by radiation brain necrosis through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients’ Karnofsky performance status (KPS) scores and brain necrosis imaging. However, necrosis is irreversible, and hypoxia and ischemia localized in the brain necrosis area may easily lead to radiation brain necrosis recurrence after bevacizumab is discontinued. Further studies are necessary to investigate brain necrosis diagnoses, bevacizumab indications, and the optimal mode of administration, bevacizumab resistance and necrosis with a residual or recurrent tumor.
Literature
1.
Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67(2):323–6.CrossRef
2.
Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neuro-Oncol. 2009;94(1):63–8.CrossRef
3.
Furuse M, Nonoguchi N, Kawabata S, Yoritsune E, Takahashi M, Inomata T, et al. Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET. Jpn J Clin Oncol. 2013;43(3):337–41.CrossRef
4.
Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-Oncology. 2013;15(9):1257–63.CrossRef
5.
Wang Y, Pan L, Sheng X, Mao Y, Yao Y, Wang E, et al. Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. Eur J Med Res. 2012;17:25.CrossRef
6.
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487–95.CrossRef
7.
Sadraei NH, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, et al. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol. 2015;38(3):304–10.CrossRef
8.
Yonezawa S, Miwa K, Shinoda J, Nomura Y, Asano Y, Nakayama N, et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. J Neuro-Oncol. 2014;119(1):101–9.CrossRef
9.
Zhuang HQ, Yuan XK, Zheng Y. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep. 2016;6:24364.CrossRef
10.
Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008;26(34):5649–50.CrossRef
11.
Alessandretti M, Buzaid AC, Brandão R, Brandão EP. Low-dose bevacizumab is effective in radiation-induced necrosis. Case Rep Oncol. 2013;6(3):598–601.CrossRef
12.
Sanborn MR, Danish SF, Rosenfeld MR, O'Rourke D, Lee JY. Treatment of steroid refractory, gamma knife related radiation necrosis with bevacizumab: case report and review of the literature. Clin Neurol Neurosurg. 2011;113(9):798–802.CrossRef
13.
Miyatake S, Nonoguchi N, Furuse M, Yoritsune E, Miyata T, Kawabata S, et al. Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain. Neurol Med Chir (Tokyo). 2015;55(Suppl 1):50–9.CrossRef
14.
Kamiryo T, Lopes MB, Kassell NF, Steiner L, Lee KS. Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery. 2001;49(2):409–14 discussion 414-5.PubMed
15.
Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neuro-Oncol. 2011;105(2):423–31.CrossRef
16.
Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335–45.CrossRef
17.
Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neuro-Oncol. 2011;102(3):471–5.CrossRef
18.
Jeyaretna DS, Curry WT Jr, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011;29(7):e159–62.CrossRef
19.
Zhuang H, Yuan X, Chang JY, Song Y, Wang J, Yuan Z, et al. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 7768.
20.
Tye K, Engelhard HH, Slavin KV, Nicholas MK, Chmura SJ, Kwok Y, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neuro-Oncol. 2014;117(2):321–7.CrossRef
21.
Chao ST, Ahluwalia MS, Barnett GH, Stevens GH, Murphy ES, Stockham AL, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys. 2013;87(3):449–57.CrossRef
22.
Chen J, Dassarath M, Yin Z, Liu H, Yang K, Wu G. Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management. Radiat Oncol. 2011;6:128.CrossRef
23.
Kessler AT, Bhatt AA. Brain tumour post-treatment imaging and treatment-related complications. Insights Imaging. 2018;9(6):1057–75.CrossRef
24.
Dashti SR, Spalding A, Kadner RJ, Yao T, Kumar A, Sun DA, et al. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain. J Neurosurg Pediatr. 2015;15(1):20–5.CrossRef
25.
Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist. 2012;17(8):1039–50.CrossRef
26.
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471–94.CrossRef
27.
Zhuang H, Yuan X, Sun D, Bian J, Chang JY, Yuan Z, et al. Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget. 7724.
28.
Eaton BR, La Riviere MJ, Kim S, Prabhu RS, Patel K, Kandula S, Oyesiku N, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neuro-Oncol. 2015 May;123(1):103–11.CrossRef
29.
Ebner D, Rava P, Gorovets D, Cielo D, Hepel JT. Stereotactic radiosurgery for large brain metastases. J Clin Neurosci. 2015;S0967-5868(15):00280–5.
30.
Zhuang H, Zheng Y, Wang J, Chang JY, Wang X, Yuan Z, et al. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget. 6532.
31.
Li Y, Huang X, Jiang J, Hu W, Hu J, Cai J, et al. Clinical variables for prediction of the therapeutic effects of bevacizumab monotherapy in nasopharyngeal carcinoma patients with radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys. 2018;100(3):621–9.CrossRef
32.
Xu Y, Rong X, Hu W, Huang X, Li Y, Zheng D, et al. Bevacizumab monotherapy reduces radiation-induced brain necrosis in nasopharyngeal carcinoma patients: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2018;101(5):1087–95.CrossRef
33.
Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017;9(4):273–80.CrossRef
Metadata
Title
Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues
Authors
Hongqing Zhuang
Siyu Shi
Zhiyong Yuan
Joe Y. Chang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2019
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-019-0950-1

Other articles of this Issue 1/2019

Molecular Cancer 1/2019 Go to the issue

Research

Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1

Research

Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy

Research

Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance

Review

Exosome-orchestrated hypoxic tumor microenvironment

Review

Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance

Research

Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits